Patients with late-stage lung and skin cancer may have just won an unlikely ally: the COVID-19 mRNA vaccine. Researchers at ...

Fintel reports that on October 20, 2025, Needham reiterated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation.

Multilateral initiatives are needed to signal confidence and fill funding gaps in mRNA research, writes Jennifer B Nuzzo ...

Over the last year, Noubar Afeyan has watched Cambridge-based Moderna go from perhaps the world’s most celebrated company ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...

An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations ...

In the current study, the association between mRNA COVID vaccination and survival was strongest among patients whose tumors ...

The mRNA technology that helped combat the global COVID-19 pandemic may now offer new hope in the fight against cancer, ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the ...

Moderately bullish activity in Moderna (MRNA), with shares up $1.95, or 7.5%, near $27.96. Options volume relatively light with 33k contracts ...

"mRNA cancer vaccines sensitize tumors to immune checkpoint inhibitors (ICIs) in part by stimulating a surge in inflammatory ...